TIP-27. An assessment of the Tumor Monorail Device (TMD) for repeated sampling as part of a trial evaluating the combination of D2C7-IT and an Fc-engineered anti-CD40 monoclonal antibody (2141-V11) administered intratumorally via convection-enhanced delivery (CED) and cervical perilymphatic injections (CPLIs) of 2141-V11 in recurrent glioblastoma (rGBM) patients
Publication
, Conference
Desjardins, A; Chandramohan, V; Mokarram, N; Meehan, S; Sharma, S; Herndon II, JE; Shoaf, M; Peters, KB; Johnson, MO; Batich, K; Low, J ...
Published in: Neuro-Oncology
November 11, 2025
Duke Scholars
Published In
Neuro-Oncology
DOI
EISSN
1523-5866
ISSN
1522-8517
Publication Date
November 11, 2025
Volume
27
Issue
Supplement_5
Start / End Page
v427 / v427
Publisher
Oxford University Press (OUP)
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1109 Neurosciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Desjardins, A., Chandramohan, V., Mokarram, N., Meehan, S., Sharma, S., Herndon II, J. E., … Bigner, D. D. (2025). TIP-27. An assessment of the Tumor Monorail Device (TMD) for repeated sampling as part of a trial evaluating the combination of D2C7-IT and an Fc-engineered anti-CD40 monoclonal antibody (2141-V11) administered intratumorally via convection-enhanced delivery (CED) and cervical perilymphatic injections (CPLIs) of 2141-V11 in recurrent glioblastoma (rGBM) patients. In Neuro-Oncology (Vol. 27, pp. v427–v427). Oxford University Press (OUP). https://doi.org/10.1093/neuonc/noaf201.1687
Desjardins, Annick, Vidya Chandramohan, Nassir Mokarram, Sean Meehan, Shaili Sharma, James E. Herndon II, Madison Shoaf, et al. “TIP-27. An assessment of the Tumor Monorail Device (TMD) for repeated sampling as part of a trial evaluating the combination of D2C7-IT and an Fc-engineered anti-CD40 monoclonal antibody (2141-V11) administered intratumorally via convection-enhanced delivery (CED) and cervical perilymphatic injections (CPLIs) of 2141-V11 in recurrent glioblastoma (rGBM) patients.” In Neuro-Oncology, 27:v427–v427. Oxford University Press (OUP), 2025. https://doi.org/10.1093/neuonc/noaf201.1687.
Desjardins A, Chandramohan V, Mokarram N, Meehan S, Sharma S, Herndon II JE, et al. TIP-27. An assessment of the Tumor Monorail Device (TMD) for repeated sampling as part of a trial evaluating the combination of D2C7-IT and an Fc-engineered anti-CD40 monoclonal antibody (2141-V11) administered intratumorally via convection-enhanced delivery (CED) and cervical perilymphatic injections (CPLIs) of 2141-V11 in recurrent glioblastoma (rGBM) patients. In: Neuro-Oncology. Oxford University Press (OUP); 2025. p. v427–v427.
Desjardins, Annick, et al. “TIP-27. An assessment of the Tumor Monorail Device (TMD) for repeated sampling as part of a trial evaluating the combination of D2C7-IT and an Fc-engineered anti-CD40 monoclonal antibody (2141-V11) administered intratumorally via convection-enhanced delivery (CED) and cervical perilymphatic injections (CPLIs) of 2141-V11 in recurrent glioblastoma (rGBM) patients.” Neuro-Oncology, vol. 27, no. Supplement_5, Oxford University Press (OUP), 2025, pp. v427–v427. Crossref, doi:10.1093/neuonc/noaf201.1687.
Desjardins A, Chandramohan V, Mokarram N, Meehan S, Sharma S, Herndon II JE, Shoaf M, Peters KB, Johnson MO, Batich K, Low J, Khasraw M, Friedman AH, Friedman HS, Ashley DM, Grant G, Osorio J, Ravetch J, Bellamkonda R, Bigner DD. TIP-27. An assessment of the Tumor Monorail Device (TMD) for repeated sampling as part of a trial evaluating the combination of D2C7-IT and an Fc-engineered anti-CD40 monoclonal antibody (2141-V11) administered intratumorally via convection-enhanced delivery (CED) and cervical perilymphatic injections (CPLIs) of 2141-V11 in recurrent glioblastoma (rGBM) patients. Neuro-Oncology. Oxford University Press (OUP); 2025. p. v427–v427.
Published In
Neuro-Oncology
DOI
EISSN
1523-5866
ISSN
1522-8517
Publication Date
November 11, 2025
Volume
27
Issue
Supplement_5
Start / End Page
v427 / v427
Publisher
Oxford University Press (OUP)
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1109 Neurosciences